1-氨基-3-吗啉基-2-丙醇 | 39849-45-1

• 物质功能分类: 生物化工 - 氨基酸及其衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 1-氨基-3-吗啉基-2-丙醇
• 中文别名: 1-氨基-3-吗啉-4-基丙烷-2-醇；1-氨基-3-(4-吗啉基)-2-丙醇；1-氨基-3-吗啉-4-基-丙-2-醇
• 英文名称: 1-amino-3-morpholin-4-yl-propan-2-ol
• 英文别名: 3-morpholino-2-hydroxypropylamine；1-Amino-3-morpholinopropan-2-ol；1-amino-3-morpholin-4-ylpropan-2-ol
• CAS: 39849-45-1
• 化学式: C₇H₁₆N₂O₂
• mdl: MFCD00462792
• 分子量: 160.216
• InChiKey: YSGPOQDTHDLUGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  58.7
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
1-Amino-3-morpholin-4-yl-propan-2-ol
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
Avoid breathing dust/fume/gas/mist/vapours/spray
P261:
P280: Wear protective gloves/protective clothing/eye protection/face protection
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
1-Amino-3-morpholin-4-yl-propan-2-ol
Ingredient name:
CAS number: 39849-45-1

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H16N2O2
Molecular weight: 160.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN2811 Class: 6.1 Packing group: III
Proper shipping name: TOXIC SOLIDS, ORGANIC, N.O.S. (1-Amino-3-morpholin-4-yl-propan-2-ol)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-氨基-3-吗啉基-2-丙醇 在 吡啶 、 sodium carbonate 作用下， 以 乙醇 为溶剂， 反应 4.0h， 生成 3-phenyl-propionic acid 2-[1,3-dimethyl-2,6-dioxo-5-(3-phenylphenylpropionyl)-1,2,3,6-tetrahydropyrimidin-4-ylamino]-1-(morpholin-4-ylmethyl)ethyl ester
  参考文献：
  名称：

  5-酰基-6- [2-羟基-3-（氨基）丙基氨基] -1,3-二烷基-1H-嘧啶-2,4-二酮的合成。

  摘要：

  逐步合成方法涉及用3-（叔氨基）-2-羟丙胺取代6-氯-1,3-二烷基尿嘧啶（5和6），随后在尿嘧啶的C5上进行酰化反应，从而合成了嘧啶二酮27-33。总产率为61-89％。已经讨论了基于NMR数据的新分子的构象方面。

  DOI：

  10.1039/b509775d
• 作为产物：
  描述：

  4-(2,3-环氧丙烷)吗啉 在 palladium dihydroxide 叠氮化锂 、 氢气 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-氨基-3-吗啉基-2-丙醇
  参考文献：
  名称：

  强大的大环肾素抑制剂的合成

  摘要：

  描述了一种有效的合成新型有效的大环肾素抑制剂的例子，该抑制剂以化合物1和2为例，其中涉及8和9的马可环化作为关键步骤。此处公开的肾素抑制剂1和2的大环设计结合了（2R，3S）-3-氨基-4-环己基-2-羟基丁酸（norACHPA）作为过渡态等排体。在P上的取代基R（吗啉代）的立体化学的测定2 '的13-元环状肾素抑制剂更有效的非对映体的位置1，2，和9被呈现。

  DOI：

  10.1016/s0040-4039(00)91716-7
• 作为试剂：
  描述：

  4-(2,3-环氧丙烷)吗啉 、 氨 在 ice water 、 1-氨基-3-吗啉基-2-丙醇 作用下， 反应 18.0h， 以to obtain the title compound 1-amino-3-morpholin-4-yl-propan-2-ol 53c (7 g, yield 99%) as a white solid的产率得到1-氨基-3-吗啉基-2-丙醇
  参考文献：
  名称：

  Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof

  摘要：

  该发明提供了由式（I）表示的新的吡咯-含氮杂环衍生物或其盐，其制备方法，含有这种衍生物的药物组合物以及将这种衍生物用作治疗剂，特别是作为蛋白激酶抑制剂的用途，其中式（I）中的每个取代基与描述中定义的相同。

  公开号：

  US08329682B2

文献信息

• PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIES,THE PREPARATION AND THE PHARMCETICAL USE THEEOF
  申请人：ChoTang Peng Cho

  公开号：US20100075952A1

  公开（公告）日：2010-03-25

  The invention provides new pyrrolo-nitrogenous heterocyclic derivatives represented by formula (I) or their salts, the preparation thereof, pharmaceutical compositions containing such derivatives and the use of such derivatives as therapeutic agents, especially as protein kinase inhibitors, wherein each substituent in formula (I) is same as defined in the description.

  该发明提供了由式(I)表示的新的吡咯基氮杂环衍生物或其盐，其制备方法，含有这种衍生物的药物组合物以及将这种衍生物用作治疗剂，特别是蛋白激酶抑制剂的用途，其中式(I)中的每个取代基与描述中定义的相同。
• Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
  申请人：SUGEN, Inc.

  公开号：US20040186160A1

  公开（公告）日：2004-09-23

  The present invention is directed to a class indolinone compounds, hexahydro-cyclohepta-pyrrole oxindoles, which are useful as protein kinase inhibitors.

  本发明涉及一类吲哚酮化合物，即六氢-环庚-吡咯酮氧吲哚，其作为蛋白激酶抑制剂具有用途。
• Treatment of acute myeloid leukemia with indolinone compounds
  申请人：SUGEN, Inc.

  公开号：US20030130280A1

  公开（公告）日：2003-07-10

  A method of treating acute myeloid leukemia in patient positive for FLT-3-ITD is described. The treatment is accomplished by administration of a compound of Formula I or II as defined herein.

  描述了一种治疗FLT-3-ITD阳性患者急性髓系白血病的方法。该治疗通过给予本文中定义的I或II式化合物来实现。
• Treatment of excessive osteolysis with indolinone compounds
  申请人：SUGEN, INC.

  公开号：US20040209937A1

  公开（公告）日：2004-10-21

  Compounds of Formula I and Formula II, as described herein, are useful for treating excessive osteolysis, by inhibiting M-CSF mediated osteoclast development. The compounds also are useful for inhibiting phosphorylation of CSF1R, and for treating cancers that express CSF1R.

  本文描述的式I和式II的化合物可用于治疗过度骨溶解，通过抑制M-CSF介导的破骨细胞发育。这些化合物还可用于抑制CSF1R的磷酸化，并用于治疗表达CSF1R的癌症。
• Heterocyclic cannabinoid receptor antagonists
  申请人：Mayweg Alexander

  公开号：US20050250769A1

  公开（公告）日：2005-11-10

  The present invention relates to compounds of formula I and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.

  本发明涉及公式I的化合物及其药用盐。这些化合物可用于治疗和/或预防与CB1受体调节相关的疾病。